and acquisitions, initial public offerings and the market performance of similar companies in the animal health and biotechnology industry sectors;???the likelihood of achieving a discrete liquidity event, such as a sale or merger, or initial public offering, given prevailing market conditions; and???external market and economic conditions and other trends and conditions affecting the pharmaceutic